Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein a vaccine against Lyme disease in healthy children and adolescents: A randomized controlled trial

Pediatrics

Volumn 108, Issue 1, 2001, Pages 123-128

  Sikand, Vijay K ^a,i   Halsey, Neal ^b   Krause, Peter J ^c   Sood, Sunil K ^d   Geller, Richard ^e   Van Hoecke, Christian ^f   Buscarino, Charles ^g   Parenti, Dennis ^g,h  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Division of Pediatric Infectious Diseases   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e Norwich Pediatric Group   (United States)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^g SmithKline Beecham   (United States)

^h WYETH AYERST RESEARCH   (United States)

ⁱ NONE   (United States)

Author keywords

Lyme disease; OspA; Pediatric; Prevention; Vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LYME DISEASE VACCINE; PLACEBO;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BORRELIA BURGDORFERI; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION PAIN; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; UNITED STATES;

ADOLESCENT; ANTIGENS, SURFACE; ARTHRALGIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI GROUP; CHILD; CHILD, PRESCHOOL; EDEMA; ERYTHEMA; EXANTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INJECTIONS; LIPOPROTEINS; LYME DISEASE; LYME DISEASE VACCINES; MALE; PAIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES;

EID: 0034956661     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.108.1.123     Document Type: Article

References (18)

1. Lyme disease - United States, 1996
2. Underreporting of Lyme disease by Connecticut physicians, 1992
3. The public health impact of Lyme disease in Maryland
4. Lyme disease update
5. Prospective assessment of Lyme disease in a school-aged population in Connecticut
6. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer surface lipoprotein A with adjuvant
7. Recommendations for the use of Lyme disease vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
8. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children
9. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults
10. Alternative vaccination schedule (0, 1, 6 versus 0, 1, 12 months) for a recombinant OspA Lyme disease vaccine
11. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme linked immunosorbent assay (ELISA)
12. Identification of LFA1 as a candidate autoantigen in treatment resistant Lyme arthritis
13. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease
14. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA immunized mice
15. Evaluation of reactogenicity and immunogenicity of booster doses of LYMErix, recombinant L-OspA vaccine against Lyme disease (LD)
16. Evaluation of the safety of booster doses of LYMErix, Lyme disease vaccine (recombinant OspA) given after three dose primary series